-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...
More »SEARCH RESULT
Total Matching Records found : 136
President Pranab Mukherjee hits out at MNCs for their ‘intent to dodge tax’
-The Times of India NAGPUR: President Pranab Mukherjee on Monday slammed multinational companies saying they only looked for oversees locations with an intention to dodge taxes, raising eyebrows at a time when the country is desperately wooing foreign capital to plug a widening current account deficit. Addressing a function at the National Academy of Direct Taxes (NADT), Mukherjee said more than three-fourths of business transactions nowadays took place through the units of...
More »The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri
-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »Most big patented drugs skip India -Rupali Mukherjee
-The Times of India Big pharma may be crying hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...
More »Novartis case may make foreign firms more wary of Indian drugs market-Ravi Ananthanarayanan
-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...
More »
